As of 2025-12-23, the Intrinsic Value of Nirvana Life Sciences Inc (NIRV.CN) is -0.36 CAD. This NIRV.CN valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.07 CAD, the upside of Nirvana Life Sciences Inc is -613.19%.
Based on its market price of 0.07 CAD and our intrinsic valuation, Nirvana Life Sciences Inc (NIRV.CN) is overvalued by 613.19%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -0.36 - -0.36 | -0.36 | -613.19% |
| DDM - Stable | 12.10 - 4.04 | 8.07 | 11431.8% |
| DDM - Multi | 12.79 - 3.12 | 5.11 | 7197.9% |
| Market Cap (mil) | 0.34 |
| Beta | -2.56 |
| Outstanding shares (mil) | 4.82 |
| Enterprise Value (mil) | 0.44 |
| Market risk premium | 5.10% |
| Cost of Equity | 2.99% |
| Cost of Debt | 5.00% |
| WACC | 3.17% |